Cell cycle corruption in a pre-leukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia

The ETV6-RUNX1 onco-fusion arises in utero, initiating a clinically silent pre-leukemic state associated with the development of pediatric B-acute lymphoblastic leukemia (B-ALL). We characterize the ETV6-RUNX1 regulome by integrating chromatin immunoprecipitation- and RNA-sequencing and show that ETV6-RUNX1 functions primarily through competition for RUNX1 binding sites and transcriptional repression. In pre-leukemia, this results in ETV6-RUNX1 antagonization of cell cycle regulation by RUNX1 as evidenced by mass cytometry analysis of B-lineage cells derived from ETV6-RUNX1 knock-in human pluripotent stem cells. In frank leukemia, knockdown of RUNX1 or its co-factor CBFβ results in cell death suggesting sustained requirement for RUNX1 activity which is recapitulated by chemical perturbation using an allosteric CBFβ-inhibitor. Strikingly, we show that RUNX1 addiction extends to other genetic subtypes of pediatric B-ALL and also adult disease. Importantly, inhibition of RUNX1 activity spares normal hematopoiesis. Our results implicate chemical intervention in the RUNX1 program as an exciting therapeutic opportunity in ALL.

[1]  E. Stanley,et al.  Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells , 2020, Cell reports.

[2]  Gary D Bader,et al.  Relapse fated latent diagnosis subclones in acute B lineage leukaemia are drug tolerant and possess distinct metabolic programs. , 2020, Cancer discovery.

[3]  Cameron S. Osborne,et al.  The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation , 2019, Cancer cell.

[4]  Ashley D. Hill,et al.  PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia , 2019, Nature Genetics.

[5]  Salam A. Assi,et al.  The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation , 2018, Cancer cell.

[6]  Yunpeng Zhou,et al.  A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells , 2018, Leukemia & lymphoma.

[7]  Gordon K Smyth,et al.  The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads , 2018, bioRxiv.

[8]  M. Greaves.  A causal mechanism for childhood acute lymphoblastic leukaemia , 2018, Nature Reviews Cancer.

[9]  A. Borkhardt,et al.  Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. , 2018, Blood.

[10]  S. Karlsson,et al.  A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1 , 2017, Developmental cell.

[11]  J. A. Pulikkan,et al.  RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. , 2017, Blood.

[12]  W. Hiddemann,et al.  Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia , 2016, Cancer cell.

[13]  René A. M. Dirks,et al.  The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. , 2016, Cell reports.

[14]  M. Nykter,et al.  Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia , 2016, Genome research.

[15]  P. Grossmann,et al.  Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks , 2016, Nucleic acids research.

[16]  Mazhar Adli,et al.  Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers , 2016, EBioMedicine.

[17]  G. Eslick,et al.  The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis , 2016, Gut.

[18]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[19]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[20]  Salam A. Assi,et al.  Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal , 2014, Cell reports.

[21]  Eric Nestler,et al.  ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases , 2014, BMC Genomics.

[22]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[23]  Carsten Peterson,et al.  Dynamic Analysis of Gene Expression and Genome-wide Transcription Factor Binding during Lineage Specification of Multipotent Progenitors , 2013, Cell stem cell.

[24]  M. Kauer,et al.  Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia , 2013, Leukemia.

[25]  E. Kremmer,et al.  The impact of TEL-AML1 (ETV6-RUNX1) expression in precursor B cells and implications for leukaemia using three different genome-wide screening methods , 2013, Blood Cancer Journal.

[26]  A. Tanay,et al.  Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. , 2013, Cell reports.

[27]  Masahiro Nakagawa,et al.  Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. , 2013, The Journal of clinical investigation.

[28]  F. Buchholz,et al.  Runx1 is essential at two stages of early murine B-cell development. , 2013, Blood.

[29]  P. Woll,et al.  Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia , 2013, Leukemia.

[30]  Thomas A. Milne,et al.  RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.

[31]  C. Mullighan.  Molecular genetics of B-precursor acute lymphoblastic leukemia. , 2012, The Journal of clinical investigation.

[32]  Matthew R Clutter,et al.  Single‐cell mass cytometry adapted to measurements of the cell cycle , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[33]  J. Gaudet,et al.  Runx1 Loss Minimally Impacts Long-Term Hematopoietic Stem Cells , 2011, PloS one.

[34]  O. Haas,et al.  The Leukemia-Specific Fusion Gene ETV6/RUNX1 Perturbs Distinct Key Biological Functions Primarily by Gene Repression , 2011, PloS one.

[35]  R. Månsson,et al.  A dose‐dependent role for EBF1 in repressing non‐B‐cell‐specific genes , 2011, European journal of immunology.

[36]  M. Farrar,et al.  Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia , 2011, The Journal of experimental medicine.

[37]  T. Enver,et al.  Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. , 2011, Blood.

[38]  Philip Machanick,et al.  MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..

[39]  T. Lister,et al.  Heterogeneous sensitivity of human Acute Myeloid Leukemia to ß-catenin down-modulation , 2011, Leukemia.

[40]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[41]  Avi Ma'ayan,et al.  ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments , 2010, Bioinform..

[42]  S. Orkin,et al.  TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. , 2009, Cell stem cell.

[43]  A. Friedman.  Cell cycle and developmental control of hematopoiesis by Runx1 , 2009, Journal of cellular physiology.

[44]  M. Greaves,et al.  The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. , 2009, The Journal of clinical investigation.

[45]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[46]  D. Kioussis,et al.  TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL , 2007, Oncogene.

[47]  S. Tsuzuki,et al.  Genetic abnormalities involved in t(12;21) TEL–AML1 acute lymphoblastic leukemia: Analysis by means of array‐based comparative genomic hybridization , 2007, Cancer science.

[48]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[49]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. König,et al.  Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1+ acute lymphoblastic leukemia: an interphase FISH analysis , 2004, Leukemia.

[51]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[52]  D. Kioussis,et al.  TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. , 2004, Blood.

[53]  M. Greaves,et al.  Origins of chromosome translocations in childhood leukaemia , 2003, Nature Reviews Cancer.

[54]  F. Mikhail,et al.  AML1 gene over-expression in childhood acute lymphoblastic leukemia , 2002, Leukemia.

[55]  S. Hiebert,et al.  Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins , 2001, Current opinion in hematology.

[56]  M. Greaves,et al.  Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. , 2000, Blood.

[57]  M. Greaves,et al.  Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia. , 1999, Cancer research.

[58]  T. Golub,et al.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription , 1996, Molecular and cellular biology.

[59]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[60]  A. Hall,et al.  A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. , 2009, Blood.